Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 4Ovarian Neoplasms 3Endometrial Neoplasms 2Small Cell Lung Carcinoma 1Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 26Paclitaxel 25Carboplatin 19Bevacizumab 13Specimen Handling 11Magnetic Resonance Spectroscopy 9Doxorubicin 8Cisplatin 8Taxes 7Biopsy 7olaparib 6lenvatinib 6Fulvestrant 6durvalumab 5dostarlimab 5Nivolumab 5Megestrol Acetate 5Letrozole 5Gemcitabine 5Docetaxel 5trastuzumab deruxtecan 4Trastuzumab 4Tirzepatide 4Progestins 4Medroxyprogesterone Acetate 4Fluorouracil 4palbociclib 3ipatasertib 3atezolizumab 3abemaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × AZD5305 × 90 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡